BSE Live
Mar 27, 16:01Prev. Close
926.75
Open Price
944.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:52Prev. Close
929.20
Open Price
935.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
940.30 (179)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Dec 04 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 8.64 | |
| Diluted EPS (Rs.) | 8.64 | |
| Cash EPS (Rs.) | 12.21 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 70.54 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 70.54 | |
| Dividend / Share(Rs.) | 1.50 | |
| Revenue from Operations/Share (Rs.) | 90.36 | |
| PBDIT/Share (Rs.) | 23.03 | |
| PBIT/Share (Rs.) | 19.46 | |
| PBT/Share (Rs.) | 11.74 | |
| Net Profit/Share (Rs.) | 8.64 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 25.48 | |
| PBIT Margin (%) | 21.53 | |
| PBT Margin (%) | 12.99 | |
| Net Profit Margin (%) | 9.55 | |
| Return on Networth / Equity (%) | 12.24 | |
| Return on Capital Employed (%) | 7.00 | |
| Return on Assets (%) | 5.38 | |
| Total Debt/Equity (X) | 0.89 | |
| Asset Turnover Ratio (%) | 56.35 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 2.11 | |
| Quick Ratio (X) | 1.89 | |
| Inventory Turnover Ratio (X) | 11.29 | |
| Dividend Payout Ratio (NP) (%) | 17.36 | |
| Dividend Payout Ratio (CP) (%) | 12.28 | |
| Earnings Retention Ratio (%) | 82.64 | |
| Cash Earnings Retention Ratio (%) | 87.72 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 914.61 | |
| EV/Net Operating Revenue (X) | 3.00 | |
| EV/EBITDA (X) | 11.76 | |
| MarketCap/Net Operating Revenue (X) | 2.36 | |
| Retention Ratios (%) | 82.63 | |
| Price/BV (X) | 3.02 | |
| Price/Net Operating Revenue | 2.36 | |
| Earnings Yield | 0.04 |
18.03.2026
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth